Human cells provide mechanistic evidence without reproducing an intact critically ill patient.
Remimazolam was continuously supplied to three-dimensional bioreactors containing primary human hepatocytes for five days. Parent drug and inactive metabolite concentrations were monitored alongside biochemical markers and CES1 expression. The investigators observed sustained metabolism without evidence of substantial cellular injury under the tested conditions.
The culture system lacks whole-body distribution, brain effects, critical-illness physiology and many co-medications. Continuous bioreactor exposure differs from intermittent two-dimensional experiments. Stable cellular metabolism does not prove absence of patient-level accumulation or establish long-term ICU outcomes.
For expert interpretation, separate enzyme activity, culture integrity and clinical recovery. Identify which concentration belongs to the culture medium rather than patient plasma. The experiment supports a metabolic-feasibility question while leaving sedation depth, organ dysfunction and the duration of recovery to clinical pharmacokinetic and outcome evidence.
Source reviewed: Metabolism of remimazolam in primary human hepatocytes during continuous long term infusion in a 3 D (PMC6450186). Forensic applications above are interpretive analysis of the supplied publication.
Related reading: Basmisanil’s Rat Memory Effects and Human Target Engagement Were Different Evidence Streams.